Essa Pharma's product candidate pipeline for prostate cancer treatment

ESSA’s primary research efforts are focused on developing small molecule therapies to treat patients with prostate cancer. Our lead candidate, EPI-7386, is a highly-selective, oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). We believe that our approach is highly differentiated and has the potential to bypass current androgen receptor-based resistance mechanisms that develop in patients with castration resistant prostate cancer (CRPC) and metastatic castration-resistant prostate cancer (mCRPC).

Trials

Clinical Monotherapy Trial

ESSA is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with mCRPC resistant to standard-of-care treatments.

Collaboration Trials

We are planning to evaluate EPI-7386 in clinical studies in combination with currently approved second-generation antiandrogen therapies as an earlier line of treatment for patients with mCRPC. Based upon preclinical studies, ESSA believes that by inhibiting both the N-terminal domain and the ligand-binding domain, greater suppression of the androgen receptor may result in greater suppression of androgen activity and potentially delay or prevent drug resistance.

EPI-7386

Program Prog	Indication Ind	Research Res
EPI-7386 monotherapy
EPI-7386 monotherapy	mCRPC - Resistant to standard of care treatments*	mCRPC - Resistant to standard of care treatments*
EPI-7386 monotherapy	Non-PC AR-Driven Cancers	Non-PC AR-Driven Cancers
EPI-7386 + enzalutamide
EPI-7386 + enzalutamide	mCRPC	mCRPC
EPI-7396 + abiraterone acetate + prednisone
EPI-7396 + abiraterone acetate + prednisone	mCRPC	mCRPC
EPI-7386 + apalutamide
EPI-7386 + apalutamide	mCRPC	mCRPC
EPI-7386 + darolutamide
EPI-7386 + darolutamide	mCRPC	mCRPC

* Phase 1 clinical update expected during the first half of 2022.
** Clinical collaborations expected to initiate in the second half of 2021. Bayer and Janssen will be conducting their respective combination trials. ESSA will be conducting the combination trial with Astellas.

Discovery

Program Prog	Indication Ind	Research Res
3rd-Generation AR N-Terminal Domain Inhibitor
3rd-Generation AR N-Terminal Domain Inhibitor	Prostate Cancer	Prostate Cancer
AR N-Terminal Domain Tau-1 Site Inhibitor
AR N-Terminal Domain Tau-1 Site Inhibitor	Prostate Cancer	Prostate Cancer
AR N-Terminal Domain Degrader
AR N-Terminal Domain Degrader	Prostate Cancer	Prostate Cancer

Product Candidates

Pipeline